HK inno.N Announces U.S. Phase 3 Results for K-CAB in Non-Erosive Reflux Disease at ACG 2026
HK inno.N Announces Positive U.S. Phase 3 Results for K-CAB in Non-Erosive Reflux Disease at ACG 2026
- U.S. partner Sebela Pharmaceuticals presents positive Phase 3 data in Non-erosive Reflux Disease (NERD)
- K-CAB stands as the first and only P-CAB reported to demonstrate clinical improvement in both hallmark symptoms of NERD, heartburn and regurgitation, in a prospective U.S. Phase 3 clinical trial
- Post hoc analysis of erosive esophagitis (EE) trial applying Lyon Consensus 2.0 receives the prestigious ACG Presidential Award

Photo. HK inno.N(left), Sebela Pharmaceuticals(right) CI.
HK inno.N announced that K-CAB (generic name: tegoprazan), its novel treatment for gastroesophageal reflux disease (GERD), met both the primary and secondary endpoints in a U.S. Phase 3 study in patient with non-erosive reflux disease(NERD), significantly improving both heartburn and regurgitation.
On October 12, HK inno.N announced that its U.S. partner, Sebela Pharmaceuticals (hereinafter “Sebela”), will present positive data results from the U.S. Phase 3 study of tegoprazan in NERD at the American College of Gastroenterology’s 2026 Annual Scientific Meeting, held in Tennessee from October 9 to 14 (local time).
Earlier in May, Sebela presented U.S. Phase 3 results evaluating tegoprazan for the healing of erosive esophagitis (EE) and the maintenance of healing at Digestive Disease Week (DDW 2026), where the results drew attention from gastroenterologists and researchers from around the world.
The presentation is based on the pivotal Phase 3 TRIUMpH program announced by Sebela last year, and will be presented on October 14 (local time) by Ronnie Fass, MD, of Case Western Reserve University School of Medicine, an internationally recognized authority on GERD.
The TRIUMpH-NERD study was a large-scale U.S. Phase 3 clinical trial enrolling 783 adult patients with NERD. Participants were randomized to receive tegoprazan 50 mg, tegoprazan 100 mg, or placebo once daily for 4 weeks, followed by a 20-week extension period. The primary endpoint was the percentage of 24-hour heartburn-free days through Week 4, and the key secondary endpoint was the percentage of days without nighttime heartburn through Week 4.
Both doses of tegoprazan met the primary and secondary endpoints. Prespecified analyses also showed improvements in days without regurgitation and days free of both heartburn and regurgitation versus placebo. Through Week 4, the least-squares (LS) mean percentage of 24-hour heartburn-free days was 17.3% with placebo, 26.2% with tegoprazan 50 mg, and 30.1% with tegoprazan 100 mg (p=0.0006 and p<0.0001, respectively). The LS mean percentage of days without nighttime heartburn was 27.0% for placebo, compared to 36.1% for tegoprazan 50 mg and 39.9% for tegoprazan 100 mg (p=0.0017 and p<0.0001, respectively).
Tegoprazan also demonstrated significant improvements in the percentage of days without regurgitation as well as complete symptom resolution (days free of both heartburn and regurgitation). For the composite endpoint evaluating days free of both symptoms, tegoprazan achieved a relative improvement over placebo of 60% in the 50 mg group and 76% in the 100 mg group.
The therapeutic efficacy of tegoprazan was sustained through the 20-week extension phase. The LS mean percentage of 24-hour heartburn-free days was 48% with tegoprazan 50 mg and 50% with 100 mg – Similar results were observed for percentage of days without regurgitation.
Separately at the meeting, a post hoc analysis applying the Lyon Consensus 2.0—the internationally recognized diagnostic criteria for GERD—to tegoprazan’s U.S. Phase 3 trial for the healing of erosive esophagitis (EE) received the ACG Presidential Award.
Presented by Walter Chan, MD, of Harvard Medical School, this analysis reclassified patients with erosive esophagitis based on Los Angeles (LA) classification grades: LA Grades B–D were classified as conclusive GERD, while LA Grade A was categorized as inconclusive GERD.
Among the 1,245 patients in the modified intention-to-treat (m-ITT) population, the Week 2 EE healing rate in patients with conclusive GERD was 75.4% for tegoprazan versus 60.7% for lansoprazole. At Week 24, among patients with conclusive GERD (LA Grades B-D). both tegoprazan 50 mg and 100 mg demonstrated superiority over lansoprazole in maintaining healing (m-ITT, p≤0.0019; per protocol, p<0.0001). In contrast, no statistically significant difference between treatment groups was observed among patients with inconclusive GERD (LA Grade A).
“For patients living with non-erosive reflux disease, meaningful clinical benefit requires addressing both heartburn and acid regurgitation—two symptoms that severely compromise the quality of daily life,” said Ronnie Fass, MD, of Case Western Reserve University School of Medicine, the presenting author. “In this study, tegoprazan delivered statistically significant relief across individual symptoms as well as the composite symptom-free endpoint.”
“Together, these NERD and EE analyses strengthen the evidence for tegoprazan across major GERD phenotypes and address persistent treatment gaps” said Alan Cooke, President and Chief Executive Officer of Sebela Pharmaceuticals. “These findings represent important progress toward our vision of advancing the treatment of GERD. We are committed to translating meaningful scientific advances into treatments that can make a difference for the millions of patients who still struggle with this disease.”
“This presentation holds immense significance as it highlights K-CAB’s proven clinical value, as demonstrated in a large-scale U.S. patient population, to the global medical community,” said an official from HK inno.N. “We will work hand-in-hand with our partner to establish K-CAB as a leading next-generation GERD therapy in the world’s largest pharmaceutical market.”
Tegoprazan is the active pharmaceutical ingredient of K-CAB, the 30th novel drug developed in South Korea by HK inno.N. As a novel potassium-competitive acid blocker (P-CAB), K-CAB has proven superiority over conventional proton pump inhibitors (PPIs) in rapid onset of action, sustained acid suppression, and the healing and maintenance of erosive esophagitis. Since its domestic launch in March 2019, K-CAB has accumulated KRW 1.0433 trillion in outpatient prescription sales through the first half of this year, maintaining the No. 1 position in Korea’s outpatient market for peptic ulcer treatments.
To date, K-CAB has entered into technology transfer or finished-product export agreements covering 55 countries worldwide. It has secured regulatory approval in 24 countries (including South Korea) and has been commercialized in 22 countries. Sebela Pharmaceuticals, HK inno.N’s U.S. development partner, submitted a New Drug Application (NDA) to the U.S. FDA in January. (END)
About TRIUMpH
The TRIUMpH program comprises phase 3 clinical studies evaluating tegoprazan in U.S. patients with gastroesophageal reflux disease (GERD), including △erosive esophagitis (EE) and △non-erosive reflux disease (NERD).All phase 3 studies were conducted as multi-center, double-blind trials involving U.S. patients representative of the country’s diverse demographics and racial composition.
■ Phase 3 NERD study (NCT05587322)
This phase 3 NERD study enrolled 800 patients and was a large, multi-center, double-blind trial designed to assess the safety and efficacy of tegoprazan versus placebo over a 4-week period.. The primary endpoint was the proportion of 24-hour heartburn-free days, and the secondary endpoints were the proportion of overnight heartburn-free days and the proportion of acid regurgitation-free days.
▶ Primary endpoint: proportion of 24-hour heartburn-free days (superior)
▶ Secondary endpoints: proportion of overnight heartburn-free days and proportion of acid regurgitation-free days (superior)
※ In both EE and NERD studies, Treatment-emergent adverse events (TEAEs) associated with tegoprazan occurred at a rate of less than 3% and were generally mild and transient.. The overall incidence rate of serious adverse events (SAEs) was less than 2% with tegoprazan, comparable to that in the control groups. The mean serum gastrin levels associated with tegoprazan remained within the normal range (0-180 pg/ml) throughout the treatment period.
■ Phase 3 EE study (NCT05587309)
This phase 3 EE study enrolled 1,250 patients, including 463 with LA Grade C/D, and was a large, multi-center, double-blind trial designed to assess the safety and efficacy of tegoprazan.This study consisted of an initial healing phase (Weeks 2 and 8/tegoprazan 100mg vs. lansoprazole 30mg) and a 24-week maintenance phase (tegoprazan 50mg and 100mg vs. lansoprazole 15mg).
▶ Primary endpoint
- Healing phase: proportion of patients achieving complete healing at Week 8
- Maintenance phase: proportion of patients maintaining complete healing at Week 24
▶ Secondary endpoints
- Healing phase: proportion of 24-hour heartburn-free days at Week 8
- Maintenance phase: proportion of 24-hour heartburn-free days at Week 24
Clinical phase | Category | Endpoint | Target patients | Result |
Healing | Primary endpoint | Cumulative complete healing rate at Week 8 (non-inferior) | Overall (LA Grade A-D) | Demonstrated |
Secondary endpoints | Proportion of 24-hour heartburn-free days (non-inferior) | Overall (LA Grade A-D) | Demonstrated | |
Cumulative complete healing rate at Week 8 (superior) | Severe (LA Grade C/D) | Demonstrated | ||
Cumulative complete healing rate at Week 2 (superior) | Severe (LA Grade C/D) | Demonstrated | ||
Cumulative complete healing rate at Week 8 (superior) | Overall (LA Grade A-D) | Demonstrated | ||
Cumulative complete healing rate at Week 2 (superior) | Overall (LA Grade A-D) | Demonstrated | ||
Maintenance | Primary endpoint | 24-week sustained healing rate (non-inferior) | Overall patients with sustained healing | Demonstrated |
Secondary endpoints | Proportion of 24-hour heartburn-free days (non-inferior) | Overall patients with sustained healing | Demonstrated | |
24-week sustained healing rate (superior) | Overall patients with sustained healing | Demonstrated | ||
24-week sustained healing rate (superior) | Severe (LA Grade C/D) | Demonstrated |
Gastroesophageal reflux disease (GERD)
- A chronic disease that causes uncomfortable symptoms such as heartburn and acid regurgitation due to the reflux of gastric contents into the esophagus and may lead to complications when the symptoms become severe, thereby repeating improvement and aggravation of symptoms.
- GERD currently affects approximately 65 million people in the U.S. The primary symptoms include heartburn and acid regurgitation. Although conventional PPI-based treatments are commonly used, 35 to 54% of patients fail to achieve complete relief of symptoms with these treatments, indicating a significant unmet need in this population.
- Based on endoscopic findings, GERD is classified into erosive and non-erosive depending on whether oesophagitis is observed.
P-CAB (Potassium Competitive Acid Blocker / HK inno.N K-CAB (Tegoprazan))
- The mechanism of P-CAB is to block the secretion of gastric acid by competitively binding directly to the potassium ions of the proton pump without the need for activation by gastric acid; i.e., by interfering with the binding of potassium ions to the proton pump.
- Therefore, P-CAB can be administered irrespective of food, provide a fast, strong effect of inhibiting gastric acid secretion from the first day of dosing, and have a long-acting property, compared to PPIs, ensuring superior prevention of overnight gastric acid secretion.
Proton Pump Inhibitors (PPI) / lansoprazole, etc.
- Gastric acid secretion is blocked by irreversible inhibition of the gastric proton pump (Hydrogen/Potassium Adenosine Triphosphatase; H+/K+-ATPase; Proton pump) involved in the final step of gastric acid secretion.
- PPIs are prodrugs that are activated by gastric acid and then bind to the proton pump for inhibition of gastric acid secretion; therefore, they should be administered before food, with the maximal effect achieved after repeated administration (3 to 5 days).
The Los Angeles Classification (LA Grade)
- LA Grade is the diagnostic criteria for erosive esophagitis (EE), first introduced by the Los Angeles Gastroenterology Association. EE is graded from LA A to LA D based on the length of mucosal breaks and their circumferential extent.
Lyon Consensus 2.0
- Diagnostic criteria established by an international panel of experts to objectively diagnose GERD and stratify patient populations. Diagnostic certainty is assessed on the basis of objective findings, including endoscopy and esophageal pH-impedance monitoring.
HK inno.N
HK inno.N was established as the pharmaceutical business division of CJ CheilJedang in 1984 and separated into CJ HealthCare Corp in 2014. After being incorporated as a subsidiary of Kolmar Group in 2018, the company was renamed HK inno.N Corp. in 2020. With a mission of "Heal the World for a Better Life," HK inno.N has advanced technologies and unrivaled expertise while specializing in prescription drugs, health supplements, and beauty products. In the business of prescription drugs, HK inno.N is focusing on creating innovative products aiming to reach global top markets, building on successful development of K-CAB, South Korea's 30th new drug, that has achieved blockbuster status. In the business of health and beauty, HK inno.N has also been committed to enhance its future growth potential through continuous expansions of its presence in the areas of beverages, health functional foods, and cosmetics, starting with launch of 'CONDITION' in the hangover cure market. www.inno-n.com
About Sebela Pharmaceuticals®
Sebela Pharmaceuticals is a U.S. pharmaceutical company with a market-leading position in Gastroenterology and a focus on innovation in women's health. Braintree Laboratories, Inc., an affiliate of Sebela Pharmaceuticals, has taken the lead in innovating, developing, manufacturing, and commercializing product categories in gastroenterology for over 40 years. The core pipeline for Braintree is a novel P-CAB tegoprazan which has completed phase 3 EE and NERD clinical trials. In 2025, Sebela Pharmaceuticals obtained FDA approval for Miudella®, a non-hormonal intrauterine device (IUD) indicated for prevention of pregnancy in women of childbearing potential. Sebela's Miudella is the first FDA-approved hormone-free IUD in over 40 years and was named to TIME’s Best Inventions of 2025 list. Sebela Pharmaceuticals also has another next-generational hormonal IUD for contraception under late-stage clinical development.
Sebela Pharmaceuticals has offices in in Roswell, GA; Braintree, MA; and Dublin, Ireland. www.sebelapharma.com